IGLV5-48: A Potential Drug Target and Biomarker (G28780)

Target Name: IGLV5-48

NCBI ID: G28780

Other Name(s): IGLV548 | Immunoglobulin lambda variable 5-48 (non-functional) | V4-3 | immunoglobulin lambda variable 5-48 (non-functional)

IGLV5-48: A Potential Drug Target and Biomarker

IGLV5-48 is a unique protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its unique structure and function make IGLV5-48 an intriguing candidate for further research and development as a new drug or diagnostic tool.

Structure and Function

IGLV5-48 is a transmembrane protein that is expressed in various tissues and cells in the body. Its structure is characterized by a long extracellular domain, a short intracellular domain, and a short cytoplasmic tail. The extracellular domain of IGLV5-48 contains a unique catalytic site that is sensitive to small molecules, making it an attractive target for drug development.

IGLV5-48 functions as a negative regulator of the NF-kappa-B signaling pathway, which is a critical pathway involved in various cellular processes, including inflammation, cell survival, and angiogenesis. The NF-kappa-B signaling pathway is a complex network of proteins that can be activated or inhibited by various factors, including small molecules, hormones, and neurotransmitters.

IGLV5-48 plays a crucial role in regulating the NF-kappa-B pathway by blocking the activity of the nuclear factor of activated T cells (NFAT), which is a transcription factor that regulates the expression of various genes involved in the NF-kappa-B pathway. By blocking the activity of NFAT, IGLV5-48 prevents the activation of NF-kappa-B and its downstream targets, thereby inhibiting the production of pro-inflammatory cytokines and limiting the severity of inflammatory responses.

IGLV5-48 has been shown to be involved in various physiological processes in the body, including cell survival, angiogenesis, and inflammation. For example, studies have shown that IGLV5-48 can promote the survival of cancer cells and contribute to their migration and invasion. Additionally, IGLV5-48 has been shown to play a role in the development of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease.

Drug Target Potential

The unique structure and function of IGLV5-48 make it an attractive candidate for drug development as a treatment for various diseases. The focus of drug development efforts is to identify small molecules that can modulate the activity of IGLV5-48 and prevent its activity from contributing to the development and progression of diseases.

One approach to drug development is to use small molecules that can inhibit the activity of IGLV5-48. Such small molecules can be found through various screening approaches, including high-throughput screening assays and chemical screening. Once potential small molecules are identified, further optimization and testing will be necessary to determine their efficacy and safety as potential drug candidates.

Biomarker Potential

IGLV5-48 has also been identified as a potential biomarker for various diseases. Its unique structure and function make it an attractive candidate for use as a diagnostic tool or target for therapeutic intervention.

One approach to biomarker development is to use small molecules that can modulate the activity of IGLV5-48 and cause a change in its expression or activity. Such small molecules can then be used to measure the level of IGLV5-48 in biological samples, such as blood or tissue, and used to diagnose or monitor the progression of diseases.

Conclusion

IGLV5-48 is a unique protein that has the potential to be a drug target and biomarker for various diseases. Its structure and function make it an attractive candidate for further research and development as a new treatment or diagnostic tool. Further studies are needed to determine the efficacy and safety of small molecules that can modulate the activity of IGLV5-48, as well as their potential utility as biomarkers for various diseases.

Protein Name: Immunoglobulin Lambda Variable 5-48 (non-functional)

Functions: Probable non-functional open reading frame (ORF) of V region of the variable domain of immunoglobulin light chains (PubMed:24600447). Non-functional ORF generally cannot participate in the synthesis of a productive immunoglobulin chain due to altered V-(D)-J or switch recombination and/or splicing site (at mRNA level) and/or conserved amino acid change (protein level) (PubMed:9619395). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170)

More Common Targets